Novel group of STAT3 pathway inhibitors and cancer stem cell pathway inhibitors

The present invention relates to the use of a novel class of cancer stem cell pathway (CSCP) inhibitors; to methods of using such compounds to treat refractory, recurrent, or metastatic cancers; to methods of selective killing cancer cells by using such compounds with specific administration regimen...

Full description

Saved in:
Bibliographic Details
Main Authors ROGOFF HARRY, LI WEI, JIANG ZHIWEI, LI YOUZHI, LI CHIANG JIA, LIU JIFENG
Format Patent
LanguageChinese
English
Published 28.09.2016
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention relates to the use of a novel class of cancer stem cell pathway (CSCP) inhibitors; to methods of using such compounds to treat refractory, recurrent, or metastatic cancers; to methods of selective killing cancer cells by using such compounds with specific administration regimen; to methods of targeting cancer stem cells by inhibiting Stat3 pathway; to methods of using novel compounds in the treatment of conditions or disorders in a mammal related to aberrant Stat3 pathway activity; and to processes for preparing such compounds and intermediates thereof, and to the pharmaceutical composition of relevant compounds, and to the specific methods of administration of these compounds. 类新的STAT3通路抑制剂和癌干细胞通路抑制剂。本发明涉及类新的癌干细胞通路(CSCP)抑制剂的用途;利用此类化合物治疗顽固性、复发性或转移性癌症的方法;通过利用此类化合物以特定施用策略选择性杀死癌细胞的方法;通过抑制Stat3通路靶向癌干细胞的方法;利用新化合物治疗哺乳动物异常Stat3通路活性相关病情或紊乱的方法;以及制备此类化合物及其中间体的方法;相关化合物的药物组合物;和施用这些化合物的具体方法。
Bibliography:Application Number: CN201610134121